Literature DB >> 21136179

Borderline resectable pancreatic cancer: what have we learned and where do we go from here?

Matthew H G Katz, Peter W T Pisters, Jeffrey E Lee, Jason B Fleming.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21136179     DOI： 10.1245/s10434-010-1460-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  14 in total

1.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

Review 2.  [Vascular replacement in abdominal tumor surgery].

Authors:  A Mehrabi; P Houben; N Attigah; D Böckler; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

3.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Authors:  Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

Review 4.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

5.  Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement.

Authors:  J Perinel; G Nappo; M El Bechwaty; T Walter; V Hervieu; P J Valette; P Feugier; M Adham
Journal:  Langenbecks Arch Surg       Date:  2016-07-30       Impact factor: 3.445

Review 6.  Management options in locally advanced pancreatic cancer.

Authors:  Omar Y Mian; Ashwin N Ram; Richard Tuli; Joseph M Herman
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

Review 7.  Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

8.  Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Authors:  Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook
Journal:  JAMA Surg       Date:  2016-08-17       Impact factor: 14.766

9.  The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Nigel B Jamieson; Nigel I J Chan; Alan K Foulis; Euan J Dickson; Colin J McKay; C Ross Carter
Journal:  J Gastrointest Surg       Date:  2013-01-08       Impact factor: 3.452

10.  Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes.

Authors:  Pavan Tummala; Todd Howard; Banke Agarwal
Journal:  Clin Transl Gastroenterol       Date:  2013-03-21       Impact factor: 4.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.